Ark Healthcare Unveils Xingshi Medical Large Model at H2H Healthcare Ecosystem Summit in Shanghai

On September 10, the 10th H2H Medical Service Ecosystem Conference (hereinafter referred to as the “H2H Ecosystem Conference”) hosted by Fangzhou Pharmaceutical was successfully held in Shanghai. Themed “AI Without Boundaries: Data-Driven Future,” the conference brought together top experts from the pharmaceutical industry, representatives of leading domestic and international biopharmaceutical companies, and frontline industry professionals. Attendees engaged in discussions on cutting-edge topics, including breakthroughs in large AI model technologies, the construction of new AI-driven healthcare paradigms, and the upgrading of AI-enabled digital intelligent marketing.

The H2H Ecosystem Conference has been held for ten consecutive sessions, continuously building an important platform for technology sharing, experience exchange, and resource matchmaking in the pharmaceutical and healthcare sectors. It holds profound significance for promoting collaborative innovation and digital-intelligent transformation within the industry.At the conference, Fangzhou Pharmaceutical officially announced the major launch of its self-developed “Digital Intelligence Core for Chronic Disease Management”—the Xingshi Medical Large Language Model. Meanwhile, the company also established strategic partnerships with Innovent Biologics Group and Zhejiang Otsuka Pharmaceutical Co., Ltd.Not only have we joined forces to inject powerful AI-driven momentum into the industry’s digital and intelligent transformation, but through innovative corporate practices, we have also provided a new practical paradigm for building a national health security system and achieving equitable access to and sharing of medical resources.

Analysys’s “Report on AI-Empowered Development of Healthcare” points out that China’s accelerating population aging and the rising trend of chronic diseases affecting younger demographics have increasingly highlighted structural shortages in high-quality medical resources. As health demands surge, healthcare professionals are facing growing workloads. According to the “Survey on Working Hours of Medical Personnel” released by authoritative media, 41.68% of healthcare workers report working more than 10 hours per day.

“Against this backdrop, we should all fully recognize that the healthcare services industry stands at a critical juncture for quality improvement and upgrading. The national guidelines on deeply implementing the ‘AI+’ initiative serve not only as a technological roadmap but also as a significant commitment to further enhancing the public’s sense of health-related gain and well-being.” At the conference, Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, emphasized that, as a company deeply rooted in chronic disease management, addressing pain points such as “uneven distribution of medical resources” and “long average service time per medical professional” has become the core starting point for Fangzhou Pharmaceutical’s AI technology research and development.

Caption: Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, delivers a keynote presentation

A robust set of data highlights the achievements of Fangzhou Pharmaceutical under its philosophy of “AI Empowerment, Innovation Accumulation”: As of June 30, 2025, the registered user base of its “AI+H2H” smart healthcare new ecosystem service platform reached 52.8 million, with 229,000 registered physicians onboarded. Monthly active users stood at a high of 11.9 million, ranking first in China for many consecutive years within the vertical medical sector. The scale of health insurance-related businesses grew rapidly quarter-on-quarter, while service quality achieved comprehensive improvements simultaneously.

AI technology has achieved significant results through its deep integration into business operations. Xie Fangmin stated, “‘AI + chronic disease management’ is not about showing off technical prowess; rather, it aims to address real problems and bring about tangible change. We are continuously strengthening the AI technological foundation to better engage in the wave of inclusive healthcare, ultimately benefiting more people.”

At the conference, Fangzhou Pharmaceutical made a major announcement of its independently developed “Super Digital Brain” and “Powerful Intelligent Hub”—the Xingshi Medical Large Language Model.

The Xingshi Medical Large Model not only breaks through technical bottlenecks but also serves as the core engine driving the digital and intelligent upgrade of internet healthcare. It establishes a foundational capability system encompassing image and speech recognition, natural language understanding, and massive storage and reasoning of pharmaceutical knowledge. Leveraging its State-of-the-Art (SOTA) performance in the medical domain, it integrates five major agents—Knowledge, Triage, Pre-consultation, Physician, and Electronic Medical Records—into a “Digital Intelligence Service Team,” achieving full-chain closed-loop coverage for chronic disease management services.

Fangzhou Pharmaceutical has deeply cultivated the acquaintance-based doctor-patient model and, leveraging the Xingshi Medical Large Model as its technological foundation, has successfully developed “Five Core AI Products” serving three major ecosystems—doctors, patients, and industry partners: AI Medication Assistant, AI Health Manager, AI Doctor’s Assistant, AI Academic Assistant, and AI Search.These five core AI products break through the constraints of time and space as well as resource barriers, establishing a closed-loop AI service ecosystem spanning from physicians to patients via 24/7 multimodal interactions, thereby fully unleashing the value of “AI + chronic disease management” services.

As the first clinical decision support tool powered by licensed literature from the Chinese Medical Association’s database, the localized “OpenEvidence”—Xingshi AI Academic Assistant—also made its debut at the conference.It not only precisely addresses critical pain points in current clinical scenarios, such as the urgent need for decision-making support and inefficient access to professional medical information, but also provides Chinese physicians with efficient and reliable intelligent support by leveraging five core advantages: extensive coverage of authoritative licensed content, enhanced precision through model upgrades, verifiable and precise source tracing, superior immersive interactive experience, and real-time updates without latency.

Medical AI is a critical livelihood initiative for the next decade; only those who boldly stand at the forefront will define the future. At the launch ceremony, Fangzhou Pharmaceutical stated that it would continue to uphold an open and collaborative approach, working hand in hand with industry partners to deepen AI technological innovation and co-build the ecosystem. The company looks forward to welcoming more like-minded partners to join forces, leveraging AI as a new engine for development to turn the blueprint of “Digitally Initiating a Healthy Future” into reality.

AI empowerment extends beyond the user and physician ends. As policies such as volume-based procurement and national medical insurance negotiations are deepened, the traditional marketing model of the pharmaceutical industry faces challenges. Leveraging the core advantages of AI technology to drive the digital and intelligent transformation of traditional models has become a key strategy for industry growth.

Multiple industry-leading companies are exploring the use of AI tools to achieve “high-quality” digital and intelligent marketing. Liu Qian, General Manager of Asymchem China, delivered a presentation titled “Intelligent Marketing Propels the Commercial Takeoff of Innovative Drugs in China.” During the roundtable discussion, representatives from Tencent Health Consulting, Pfizer, Innovent Biologics Group, Bristol-Myers Squibb, and Organon all affirmed that AI has become an effective tool for enhancing R&D efficiency and driving business growth.

In response to the needs highlighted by guests, such as “precise data analytics, effective user conversion, and improved physician efficiency,” Fangzhou Pharmaceutical has developed an upgraded benchmark solution for “AI + Digital Marketing.”“The head of business at Fangzhou Pharmaceutical stated, ‘Our goal is to enable AI to transcend its role as a mere tool and evolve into a “super collaborator,” unlocking greater commercial value while precisely activating user conversions and efficiently enhancing marketing effectiveness, thereby achieving a comprehensive reshaping of value across the entire chain.’”

Specifically, first, by leveraging the algorithmic capabilities of the Xingshi Medical Large Model, we summarize high-quality advertising characteristics and extract multi-dimensional tags to reduce placement costs and improve placement efficiency, thereby providing pharmaceutical companies with precise market insights. Second, the AI Health Steward has become a round-the-clock health management partner for users; through continuous real-time interaction, it not only lowers users’ decision-making costs but also effectively enhances their health literacy and self-management capabilities. Finally, the application of the AI Physician Assistant establishes a new model for doctor-patient communication, effectively shortening the time spent on repetitive exchanges and significantly improving physicians’ efficiency in patient management.

As one of the major highlights of the conference, Fangzhou Pharmaceutical officially announced deep strategic collaborations with Innovent Biologics Group and Zhejiang Otsuka Pharmaceutical Co., Ltd., ushering in a new era of resource sharing and co-created value.

Leveraging its technological expertise and ecosystem development in AI-driven chronic disease management, Fangzhou Pharmaceutical will engage in multi-dimensional, multi-level deep collaboration with two major pharmaceutical companies, focusing on comprehensive health management across all disease types. Together, they aim to further refine the end-to-end ecosystem loop of “AI + Chronic Disease Management,” delivering higher-quality, accessible health services to patients while providing a replicable model for the digital and intelligent transformation of the pharmaceutical industry.

Riding the Wave of “AI+”: The Time for AI in Healthcare Is Now! The 10th H2H Medical Service Ecosystem Conference, hosted by Fangzhou Pharmaceutical, Has Outlined a Clear Path for Collaborative Industry Development.

With the release of the Xingshi Medical Large Model and the advancement of strategic collaborations, Fangzhou Pharmaceutical will continue to deepen AI technological innovation and ecosystem synergy. Working hand in hand with partners across its ecosystem, the company is steadily advancing toward the goal of “making health and well-being accessible to hundreds of millions,” thereby injecting stronger momentum into the realization of the “Healthy China 2030” initiative.